Haemophilus parasuis cDNA and Antigen

Haemophilus parasuis is a bacterial pathogen that causes Glässer’s disease, a systemic infection in pigs that can lead to pneumonia, arthritis, and meningitis. To combat this disease, researchers are exploring potential vaccine targets, including lipoprotein C-GS60 and protective surface antigen D15.

Lipoprotein C-GS60 is a highly conserved antigen that has been shown to be immunogenic in pigs. It is considered a potential vaccine candidate for H. parasuis infections. Protective surface antigen D15 is another potential vaccine target, as it has been shown to elicit a protective immune response in animal models.

In addition to these antigens, surface antigen D15 is also being studied for its potential as a vaccine candidate. Understanding the role of these antigens in the pathogenicity of H. parasuis is important for the development of effective vaccines and treatments for Glässer’s disease.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

Diagnostics: cDNA from H. parasuis can be used to develop molecular diagnostic tools such as PCR (Polymerase Chain Reaction) assays for the rapid and specific detection of the bacterium in infected pigs.

Vaccine development: Recombinant antigens of H. parasuis can be used as potential vaccine candidates to protect pigs against the disease. Recombinant antigens have shown to provide protective immunity against challenge with the wild-type H. parasuis strain in preclinical trials.

Serotyping: The recombinant antigens can also be used for serotyping of H. parasuis isolates, which is important for understanding the diversity of the bacterium and for the development of new vaccines.

Overall, the application of cDNA and recombinant antigens of H. parasuis has the potential to contribute to the control and prevention of Glässer’s disease, which will benefit the swine industry by reducing the economic losses associated with the disease.